NL930131I2 - Hybride cel-lijn voor het voortbrengen van complementvastzetten van monocloon antilichaam aan menselijke T cellen, antilichaam en werkwijzen. - Google Patents

Hybride cel-lijn voor het voortbrengen van complementvastzetten van monocloon antilichaam aan menselijke T cellen, antilichaam en werkwijzen.

Info

Publication number
NL930131I2
NL930131I2 NL930131C NL930131C NL930131I2 NL 930131 I2 NL930131 I2 NL 930131I2 NL 930131 C NL930131 C NL 930131C NL 930131 C NL930131 C NL 930131C NL 930131 I2 NL930131 I2 NL 930131I2
Authority
NL
Netherlands
Prior art keywords
antibody
cells
cell line
human
hybrid cell
Prior art date
Application number
NL930131C
Other languages
English (en)
Dutch (nl)
Other versions
NL930131I1 (nl
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21871750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL930131(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of NL930131I1 publication Critical patent/NL930131I1/nl
Publication of NL930131I2 publication Critical patent/NL930131I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hybrid Cells (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL930131C 1979-04-26 1993-07-02 Hybride cel-lijn voor het voortbrengen van complementvastzetten van monocloon antilichaam aan menselijke T cellen, antilichaam en werkwijzen. NL930131I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/033,669 US4361549A (en) 1979-04-26 1979-04-26 Complement-fixing monoclonal antibody to human T cells, and methods of preparing same

Publications (2)

Publication Number Publication Date
NL930131I1 NL930131I1 (nl) 1993-11-01
NL930131I2 true NL930131I2 (nl) 1998-07-01

Family

ID=21871750

Family Applications (1)

Application Number Title Priority Date Filing Date
NL930131C NL930131I2 (nl) 1979-04-26 1993-07-02 Hybride cel-lijn voor het voortbrengen van complementvastzetten van monocloon antilichaam aan menselijke T cellen, antilichaam en werkwijzen.

Country Status (22)

Country Link
US (1) US4361549A (US06534493-20030318-C00166.png)
EP (1) EP0018795B2 (US06534493-20030318-C00166.png)
JP (2) JPS55145617A (US06534493-20030318-C00166.png)
AT (1) ATE14023T1 (US06534493-20030318-C00166.png)
AU (1) AU544791B2 (US06534493-20030318-C00166.png)
CA (1) CA1182406A (US06534493-20030318-C00166.png)
DE (2) DE18795T1 (US06534493-20030318-C00166.png)
DK (1) DK154769C (US06534493-20030318-C00166.png)
ES (1) ES8105152A1 (US06534493-20030318-C00166.png)
FI (1) FI75183C (US06534493-20030318-C00166.png)
HK (1) HK23886A (US06534493-20030318-C00166.png)
IE (1) IE50422B1 (US06534493-20030318-C00166.png)
IL (1) IL59917A (US06534493-20030318-C00166.png)
MY (1) MY8600514A (US06534493-20030318-C00166.png)
NL (1) NL930131I2 (US06534493-20030318-C00166.png)
NO (1) NO159221C (US06534493-20030318-C00166.png)
NZ (1) NZ193469A (US06534493-20030318-C00166.png)
PH (1) PH16642A (US06534493-20030318-C00166.png)
PT (1) PT71147B (US06534493-20030318-C00166.png)
SG (1) SG6686G (US06534493-20030318-C00166.png)
YU (1) YU48442B (US06534493-20030318-C00166.png)
ZA (1) ZA802525B (US06534493-20030318-C00166.png)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4657852A (en) * 1982-04-02 1987-04-14 The Board Of Trustees Of The Leland Stanford Junior University Method for B cell typing of total human lymphocyte sample
US4471056A (en) * 1982-04-02 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for HLA-DR typing of total human lymphocyte sample
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4797475A (en) * 1983-05-20 1989-01-10 The Regents Of The University Of California Method and composition for isolating white cell elements
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4661446A (en) * 1985-02-19 1987-04-28 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies and method of immunizing therewith
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
CA1306430C (en) * 1987-10-16 1992-08-18 Kenneth Francis Bradstock Monoclonal antibody
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
JPH0291833U (US06534493-20030318-C00166.png) * 1988-12-29 1990-07-20
JPH0277212U (US06534493-20030318-C00166.png) * 1989-01-25 1990-06-13
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
JPH0420550U (US06534493-20030318-C00166.png) * 1990-06-11 1992-02-20
US5444155A (en) * 1991-09-10 1995-08-22 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5250426A (en) * 1991-10-22 1993-10-05 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
EP2057999A3 (en) 1995-12-22 2009-07-29 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
ES2322877T3 (es) 1996-08-30 2009-06-30 Human Genome Sciences, Inc. Interleucina 19.
EP1034003A4 (en) 1997-11-24 2004-07-14 Johnson T Wong METHODS FOR TREATING HIV OR OTHER INFECTIONS USING A T CELL ACTIVATOR OR A VIRAL ACTIVATOR AND ANTIRETROVIRAL COMBINATION THERAPY
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
JP4084997B2 (ja) * 2000-11-08 2008-04-30 エフエックスエス・ベンチャーズ・エルエルシー 防腐剤増強剤として単純糖類を含有する改良眼科用およびコンタクトレンズ用溶液
US20070110782A1 (en) * 2000-11-08 2007-05-17 Fxs Ventures, Llc L-histidine in ophthalmic solutions
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
WO2002040062A2 (en) * 2000-11-08 2002-05-23 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
WO2004091438A2 (en) * 2003-04-15 2004-10-28 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions containing peptides as representative enhancers
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
ES2393674T3 (es) * 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
SG10201504917PA (en) * 2005-07-11 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
BRPI0713426A2 (pt) * 2006-06-14 2012-10-09 Macrogenics Inc métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
WO2008079713A2 (en) * 2006-12-21 2008-07-03 Macrogenics Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
ES2652340T3 (es) 2009-07-17 2018-02-01 Bioatla Llc Selección y evolución simultáneas e integradas de rendimiento y expresión de proteínas humanas en huéspedes de producción
KR20130066626A (ko) 2010-04-29 2013-06-20 나스벡스 엘티디. 항ｃｄ3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
CN105924499B (zh) 2010-07-16 2020-09-15 生物蛋白有限公司 蛋白演化的新方法
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
ES2899186T3 (es) 2010-12-31 2022-03-10 Bioatla Inc Humanización rápida de anticuerpos
CA2997473C (en) 2010-12-31 2023-10-03 Bioatla, Llc Comprehensive monoclonal antibody generation
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
KR102023401B1 (ko) 2012-05-10 2019-11-04 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AU2015204840B2 (en) 2014-01-07 2020-01-30 Bioatla, Llc Proteins targeting orthologs
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3132247B1 (en) 2014-04-16 2021-08-18 Juno Therapeutics GmbH Methods, kits and apparatus for expanding a population of cells
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
MX2017009535A (es) 2015-01-23 2017-11-02 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
JP7195141B2 (ja) 2015-10-22 2022-12-23 ジュノ セラピューティクス ゲーエムベーハー 形質導入のための方法、キット、作用物質および装置
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
EP3411407B1 (en) 2016-02-05 2024-04-03 Orionis Biosciences BV Bispecific signaling agents and uses thereof
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
AR111625A1 (es) 2017-04-27 2019-07-31 Juno Therapeutics Gmbh Reactivos de partículas oligoméricas y métodos de uso de los mismos
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
CN113272018A (zh) 2018-11-06 2021-08-17 朱诺治疗学股份有限公司 产生基因工程化t细胞的方法
WO2021064069A1 (en) 2019-10-02 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of adult t-cell leukemia/lymphoma
KR20220101641A (ko) 2019-10-30 2022-07-19 주노 테라퓨틱스 게엠베하 세포 선택 및/또는 자극 장치 및 사용 방법
KR20220152227A (ko) 2020-02-12 2022-11-15 주노 쎄러퓨티크스 인코퍼레이티드 Ｂｃｍａ-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
AU2021220875A1 (en) 2020-02-12 2022-09-29 Juno Therapeutics, Inc. CD19-directed chimeric antigen receptor T cell compositions and methods and uses thereof
CN115697403A (zh) 2020-03-10 2023-02-03 迪赞纳生命科学公开有限公司 Il-6/il-6r抗体的组合物及其使用方法
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
CN115768878A (zh) 2020-06-17 2023-03-07 迪赞纳生命科学公开有限公司 用于增强嵌合抗原受体(car) t细胞疗法的组合物和方法
IL299744A (en) 2020-07-30 2023-03-01 Tiziana Life Sciences Plc Antibodies to CD-3 for the treatment of the corona virus
WO2022221767A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
CA3234994A1 (en) 2021-10-14 2023-04-20 Tiziana Life Sciences Plc Methods of suppressing microglial activation
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023147331A1 (en) 2022-01-26 2023-08-03 Mabswitch Inc. Bispecific molecule with tunable affinity to a targetted antigen
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR956062A (US06534493-20030318-C00166.png) * 1950-01-24
GB824492A (en) * 1955-10-07 1959-12-02 Frederick William Beinlich Process and apparatus for the generation of power
US3988895A (en) * 1974-01-11 1976-11-02 Itzhak Sheinbaum Power generation from hot brines
US3986362A (en) * 1975-06-13 1976-10-19 Petru Baciu Geothermal power plant with intermediate superheating and simultaneous generation of thermal and electrical energy
US4089175A (en) * 1975-06-23 1978-05-16 Occidental Petroleum Corporation Process and system for recovery of energy from geothermal brines and other water containing sources by direct contact with a working fluid below the critical pressure
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
BE875277A (fr) * 1979-04-02 1979-10-02 Jourdain Leon J Machine motrice
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
FI801342A (fi) 1980-10-27
DE18795T1 (de) 1984-07-19
YU48442B (sh) 1998-07-10
DK154769B (da) 1988-12-19
ES490944A0 (es) 1981-05-16
MY8600514A (en) 1986-12-31
JPH0198478A (ja) 1989-04-17
AU544791B2 (en) 1985-06-13
HK23886A (en) 1986-04-11
US4361549A (en) 1982-11-30
DE3070803D1 (en) 1985-08-01
FI75183C (fi) 1988-05-09
NO801214L (no) 1980-10-27
NO159221C (no) 1988-12-07
IL59917A (en) 1983-12-30
ES8105152A1 (es) 1981-05-16
ZA802525B (en) 1981-12-30
EP0018795B1 (en) 1985-06-26
AU5775780A (en) 1980-10-30
PH16642A (en) 1983-12-06
DK154769C (da) 1989-06-19
ATE14023T1 (de) 1985-07-15
PT71147A (en) 1980-05-01
EP0018795A2 (en) 1980-11-12
EP0018795A3 (en) 1981-01-07
PT71147B (en) 1981-08-11
FI75183B (fi) 1988-01-29
JPS55145617A (en) 1980-11-13
SG6686G (en) 1986-08-01
EP0018795B2 (en) 1999-04-07
DK180380A (da) 1980-10-27
IE50422B1 (en) 1986-04-16
NL930131I1 (nl) 1993-11-01
NO159221B (no) 1988-08-29
IE800840L (en) 1980-10-24
YU114680A (en) 1984-02-29
CA1182406A (en) 1985-02-12
JPH0159868B2 (US06534493-20030318-C00166.png) 1989-12-20
JPS6362520B2 (US06534493-20030318-C00166.png) 1988-12-02
IL59917A0 (en) 1980-06-30
NZ193469A (en) 1984-07-06

Similar Documents

Publication Publication Date Title
NL930131I2 (nl) Hybride cel-lijn voor het voortbrengen van complementvastzetten van monocloon antilichaam aan menselijke T cellen, antilichaam en werkwijzen.
NO159888C (no) Monoklonalt antistoff.
NO159883C (no) Monoklonalt antistoff.
NO159882C (no) Monoklonalt antistoff.
NO159885C (no) Monoklonalt antistoff.
NO159887C (no) Monoklonalt antistoff.
NO159886C (no) Monoklonalt antistoff.